Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberta Caputo

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Recenti Progressi in Medicina|June 16, 2026
Roberta Caputo
Future Oncology (London, England)|May 9, 2017
Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case reportRoberta Caputo, Daniela Cianniello, Michelino De Laurentiis
Frontiers in Oncology|August 21, 2023
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case reportRoberta Caputo, Martina Pagliuca, Matilde Pensabene, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2025
In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast CancerMichelino De Laurentiis, Roberto Buonaiuto, Giuseppe Buono, et al.
Breast Cancer (Dove Medical Press)|October 21, 2022
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 TrialRoberta Caputo, Alessandra Fabi, Emanuela Romagnoli, et al.
Current Medicinal Chemistry|December 6, 2019
Gene Expression Assay in the Management of Early Breast CancerRoberta Caputo, Daniela Cianniello, Antonio Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancerRoberto Bianco, Roberta Caputo, Rosa Caputo, et al.
American Journal of Translational Research|September 21, 2016
Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patientsFrancesca Collina, Margherita Cerrone, Valentina Peluso, et al.
International Journal of Molecular Sciences|July 2, 2020
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future PerspectivesStefania Cocco, Michela Piezzo, Alessandra Calabrese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activityGiampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Recenti Progressi in Medicina|June 16, 2026
Roberta Caputo
Future Oncology (London, England)|May 9, 2017
Eribulin as an effective monotherapy in a chemo-pretreated woman with metastatic breast cancer: a case reportRoberta Caputo, Daniela Cianniello, Michelino De Laurentiis
Frontiers in Oncology|August 21, 2023
Long-term complete response with third-line PARP inhibitor after immunotherapy in a patient with triple-negative breast cancer: a case reportRoberta Caputo, Martina Pagliuca, Matilde Pensabene, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2025
In Defense of Adjuvant CDK4/6 Inhibitors in Early Breast CancerMichelino De Laurentiis, Roberto Buonaiuto, Giuseppe Buono, et al.
Breast Cancer (Dove Medical Press)|October 21, 2022
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 TrialRoberta Caputo, Alessandra Fabi, Emanuela Romagnoli, et al.
Current Medicinal Chemistry|December 6, 2019
Gene Expression Assay in the Management of Early Breast CancerRoberta Caputo, Daniela Cianniello, Antonio Giordano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2004
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancerRoberto Bianco, Roberta Caputo, Rosa Caputo, et al.
American Journal of Translational Research|September 21, 2016
Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patientsFrancesca Collina, Margherita Cerrone, Valentina Peluso, et al.
International Journal of Molecular Sciences|July 2, 2020
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future PerspectivesStefania Cocco, Michela Piezzo, Alessandra Calabrese, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activityGiampaolo Tortora, Rosa Caputo, Vincenzo Damiano, et al.
Pageof 5